EZH2 inhibition by 3-Deazaneplanocin A (DZNep) has been proposed a proof-of-concept for epigenetic therapy of liver fibrosis, which is one of the most potent S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors with broad effects on histone lysine methyltransferase activities, and a widely used H3K27me3 methyltransferase inhibitor of EZH2 for anti-cancer therapeutic development 10. The gene discussed is EZH2; the disease is Hepatic fibrosis.